Associated Papers
Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients.
Dhangar S et al.
Leukemia Research, 2025
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J et al.
Journal of Translational Medicine, 2020
32738923 (PubMed )
Supplement: 12967_2020_2449_MOESM2_ESM.xlsx › Supplementary_Table_S1
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
32283832 (PubMed )
Supplement: cancers-12-00927-s001.pdf
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-ABL1
Mutations Associated with Imatinib Mesylate Resistance - Review.
Linev AJ et al.
Folia Medica, 2018
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T et al.
Nature, 2015
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S et al.
Leukemia Research, 2014
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S et al.
American Journal of Hematology, 2012
Select a paper to view details